Lutz Giebel, PHD
Dr. Lutz Giebel, the executive chairman Orange Grove Bio ("OGB"), is a Biotech Entrepreneur based in the San Francisco Bay Area. He is currently co-founder and Chairman of Relinia Inc and Implicyte Inc. Previously Lutz was co-founder, Director and CEO of Delinia Inc. In January 2017 the company was acquired by Celgene for $775 million, four months after the company announced its Series A financing. Prior Lutz was a Managing Partner at SV Life Sciences, an international healthcare focused Venture Capital firm. He was there for 13 years focusing on bio-therapeutics in the U.S. Before that, he was a Managing Partner of Didyma LLC, a biotechnology management consulting firm. Lutz was Founder, President and CEO of CyThera Inc., now ViaCyte and Founder and Chief Operating Officer of ExSAR. He was Founder and Vice President of Research at MetaXen, LLC, which was sold to Exelixis. He joined Axys Pharmaceutical, sold to Celera, as the first biologist and subsequently held various management positions, including Senior Director of Molecular Biology. He hopes to use these experiences to guide Orange Grove Bio and their constituents through the startup minefield.
Lutz served on the boards of Alba, Allocure, Avera, Cyterix, Delinia, Good Start Genetics, Logical Therapeutics, Lux Biosciences, Neurotech, Ophthotech, Panoptica, Sapphire, Delinia, Relinia and Implicyte.
Lutz received his PhD in Molecular Biology at the University of Heidelberg, Germany and did his Post Doctoral studies in Human Genetics at the University of Wisconsin, Madison.